Subclavian Vein Diameter Variations to Assess Vascular Filling
NCT ID: NCT04946643
Last Updated: 2025-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2021-07-27
2022-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although the first line of treatment is often vascular filling, many studies have found that excessive vascular filling alone is deleterious and leads to increased morbidity and mortality due to pulmonary and interstitial oedema. The use of catecholamines avoids this undue vascular filling.
At present, the therapeutic strategy in acute circulatory failure is to perform a personalised "titrated" vascular filling after assessing the need for it.
To do this, predictive criteria for the need to continue vascular filling in order to optimise cardiac output and tissue perfusion pressure, particularly by ultrasound, have been developed, notably by transesophageal approach.
It also appeared to us that offering an alternative to the transesophageal approach would reduce invasiveness on the one hand, but would also offer an alternative when the transesophageal approach is contraindicated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bedside Visual Analysis of Sublingual Microcirculation in Shock Patients
NCT03406598
Simplified Inferior Vena Cava Collapsiblity
NCT06921642
Central Venous Pressure Versus Inferior Vena Cava Distensibility Index in Assessing Fluid Responsiveness in Septic Shocked Patients
NCT07279064
Reliability of Ultrasound Examination of the Inferior Caval Vein
NCT04488627
Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter
NCT02231463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been observed that organ failure induced by circulatory insufficiency is associated with a poor prognosis in septic shock. In daily clinical practice, acute circulatory failure is most often characterised by haemodynamic failure as reflected by arterial hypotension and/or tachycardia. Early treatment of acute circulatory failure is a recognised prognostic factor in trauma patients and patients with septic shock (2,3), leading to a reduction in mortality.
The first line of treatment for circulatory failure is usually early vascular filling due to relative and absolute hypovolaemia. The choice of fluids depends on the clinical situation, although for septic shock crystalloids are recommended as first-line therapy. Although early vascular filling is the first line of treatment, overfilling, also known as "induced" vascular filling, is alone recognised as a factor associated with excess mortality in various situations of acute circulatory failure. It is now accepted that early administration of inotropic and/or vasopressor agents, i.e. before the end of vascular filling, is necessary to restore arterial pressure and therefore limit the consequences of tissue hypo perfusion. In order to determine the choice between continued vascular filling and the administration of vasopressor and/or inotropic agents, predictive indicators of vascular filling requirements have been developed. These aim to determine whether or not vascular filling will increase cardiac output or one of its surrogates such as the subaortic time velocity integral (SATI).
Numerous indicators have been described for more than 30 years in intensive care units. Dynamic criteria are those that have the best predictive performance compared to static indicators. Their time-consuming implementation requires an invasive approach for most of these criteria due to their technical nature and the need to respect sometimes restrictive validity criteria.
The technological development of ultrasound scanners has allowed their liberal use and the validation of dynamic ultrasound criteria predictive of the response to vascular filling (respiratory variations of the sub-aortic velocity time integral, S wave, index of distensibility of the inferior vena cava, index of collapsibility of the superior vena cava, central venous pressure). The mechanism underlying superior vena cava collapsibility is complex, involving variations in intra-thoracic pressure as well as the inherent movements of the lung parenchyma. These pathophysiological mechanisms have not yet been described.
A recent study has demonstrated the interchangeability between delta PP and respiratory variations in subclavian vein diameter in intensive care patients and in the operating theatre.
The advantages of the transthoracic ultrasound approach to assessing respiratory variations in subclavian vein diameter are its rapidity of implementation, ease of use, non-invasive nature and reproducibility.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute circulatory failure from any cause defined as low blood pressure (systolic blood pressure less than 90mmHg and/or mean arterial pressure less than 65mmHg) and/or marbling and mechanical ventilation;
* Affiliation with a social security scheme or entitled to it;
* Information and non-objection of the patient to participate in the research.
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Romain Jouffroy, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Intensive care unit, Ambroise Paré hospital, APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive care unit, Ambroise Paré hospital, APHP
Boulogne-Billancourt, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A00694-37
Identifier Type: REGISTRY
Identifier Source: secondary_id
APHP210513
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.